SCHEMBL4862902

SCHEMBL4862902

O=c1c([N+](=O)[O-])c(-c2cnn(-c3ccccc3)c2)n(C(F)c2ccccc2)c(=O)n1C(F)c1ccccc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSP90AA1 P07900 1/20 0.47
KDM5B Q9UGL1 2/20 0.36
ADORA2A P29274 1/20 0.36
ADORA2B P29275 1/20 0.36
ADORA1 P30542 1/20 0.36
GRM4 Q14833 7/20 0.36
HTR2B P41595 1/20 0.35
MTNR1A P48039 1/20 0.35
KCNH2 Q12809 1/20 0.35
KDM5A P29375 1/20 0.34
ALDH1A1 P00352 3/20 0.33
MAPT P10636 3/20 0.33
KMT2A Q03164 2/20 0.33
GRM2 Q14416 1/20 0.33
MEN1 O00255 1/20 0.33
SMN1; SMN2 Q16637 2/20 0.33
CYP1A2 P05177 2/20 0.33
HPGD P15428 2/20 0.33
CYP2C19 P33261 2/20 0.33
GAA P10253 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4866434 0.86 BRD4 (0.38) ALDH1A1KMT2AGRM2MEN1HPGD
SCHEMBL4859896 0.85 HSP90AA1 (0.47) HSP90AA1KDM5BADORA2AADORA2BADORA1
SCHEMBL4867858 0.81 PDE1A (0.39) HSP90AA1GRM4KCNH2ALDH1A1MAPT
SCHEMBL4769555 0.81 NPC1 (0.41) HSP90AA1ALDH1A1MAPTKMT2AMEN1
SCHEMBL4769549 0.81 NPC1 (0.41) HSP90AA1ALDH1A1MAPTKMT2AMEN1
SCHEMBL4866206 0.81 HSP90AA1 (0.47) HSP90AA1KDM5BADORA2AADORA2BADORA1
SCHEMBL4864909 0.79 ADORA2B (0.43) ADORA2AADORA2BADORA1KCNH2ALDH1A1
SCHEMBL4916172 0.77 ADORA2B (0.45) ADORA2AADORA2BADORA1ALDH1A1
SCHEMBL4868133 0.76 HSP90AA1 (0.43) HSP90AA1KDM5BADORA2AADORA2BADORA1
SCHEMBL4767578 0.75 DCTPP1 (0.38) ALDH1A1MAPTKMT2AMEN1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7449473-B2 Substituted pyrrolo[3,2-d]pyrimidin-2,4-diones as A2b adenosine receptor antagonists CV THERAPEUTICS, INC. (US) 2008-11-11 US disclosed
EP-1678181-A2 A2B ADENOSINE RECEPTOR ANTAGONISTS CV THERAPEUTICS, INC. (US) 2006-07-12 EP disclosed
US-20050119287-A1 A2B adenosine receptor antagonists GILEAD PALO ALTO, INC. 2005-06-02 US disclosed
WO-2005042534-A2 A2B ADENOSINE RECEPTOR ANTAGONISTS CV THERAPEUTICS, INC. (US) 2005-05-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050119287-A1 A2B adenosine receptor antagonists ADORA2B, ADORA2A, ADORA3 HSP90AA1 1863/4885KDM5B 2051/4885ADORA2A 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.